Delivering on the promise of gene therapy.
uniQure is a world leader in the research and early development of human gene based therapies. uniQure has obtained market authorization for Glybera (a gene therapy treatment for lipoprotein lipase deficiency) in Europe and has a product pipeline of several gene therapies in development: hemophilia B, acute intermittent porphyria, Parkinson’s disease and Sanfilippo. uniQure is the world leader for manufacturing of AAV-based products on a commercial scale, meeting cGMP requirements, and has extensive experience in the regulatory processes for gene therapies. uniQure is listed on Nasdaq and is traded under the symbol QURE.